tachycardia semaglutide causing events in afib patients? Higher-Dose Semaglutide Injection Proves Mettle

Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction

Likewise, as patients progress and require triple therapy, these medication classes comprise options in combination with a variety of other antihyperglycemic medication classes

Clinical data show that lean body mass can account for up to 1540% of the total weight lost when using GLP-1 therapies

Consistent with this finding, no improvement in glucose tolerance was observed during an intraperitoneal glucose tolerance test in C57BL6 mice that were administered a subcutaneous dose of PF-06882961 (10 mg/kg) (Fig